Emad AlShwaimi, Abdul Majeed, Aiman A Ali
Journal: Journal of endodontics 2017;42(1):30-5
PMID: 26525553
INTRODUCTION
This clinical trial was conducted to evaluate the response of human dental pulp to direct capping with betamethasone/gentamicin (BG) cream and mineral trioxide aggregate (MTA). We hypothesized that the results of direct pulp capping with a topical BG combination would be similar to or better than those with MTA.
METHODS
Thirty-six human first premolar teeth scheduled for orthodontic extraction were randomly divided into 4 groups: BG1 group (n = 9), BG cream with 2-week follow-up; BG2 group (n = 10), BG cream with 8-week follow-up; MTA1 group (n = 8), MTA with 2-week follow-up; and MTA2 group (n = 9), MTA with 8-week follow-up. Teeth were extracted and evaluated at respective time intervals. Micro-computed tomography scanning and histologic analyses were performed for all specimens. Pulp pathology (inflammation, pulp abscesses, and pulp necrosis) and reparative reaction (formation of dentin bridges) were recorded.
RESULTS
Both BG cream and MTA resulted in significantly better pulpal responses at 8 weeks than at 2 weeks. Dentin bridge formation was significantly thicker in the MTA group at 8 weeks than in any other group (P < .05). Inflammation was of the acute type in all groups; no statistically significant differences in the distribution of inflammatory cells were found among the groups. Pulpal abscesses and/or necrosis were observed more often in teeth capped with BG than with MTA.
CONCLUSIONS
Direct pulp capping with both BG cream and MTA was associated with dentin bridge formation. MTA resulted in a significantly better pulpal response, with less inflammation and a thicker dentin bridge at 8 weeks.
Copyright © 2016 American Association of Endodontists. Published by Elsevier Inc. All rights reserved.
Other Literature Sources:
Miscellaneous:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.